| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $552,042 | 8 | 100 |
| Keutzer Timothy | Chief Operating Officer | 0 | $0 | 4 | $145,193 | $-145,193 |
| Rajavelu Esther | See Remarks | 0 | $0 | 4 | $406,849 | $-406,849 |
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously …
Over the last 12 months, insiders at Spero Therapeutics, Inc. have bought $0 and sold $552,042 worth of Spero Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Spero Therapeutics, Inc. have bought $7.17M and sold $296,071 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 39,727 shares for transaction amount of $207,971 was made by Aquilo Capital, L.P. () on 2022‑04‑26.
| 2026-05-04 | Sale | Rajavelu Esther | See Remarks | 25,240 0.0438% | $2.51 | $63,352 | -50.80% | |
| 2026-02-06 | Sale | Rajavelu Esther | See Remarks | 87,917 0.1522% | $2.36 | $207,484 | -9.30% | |
| 2026-02-06 | Sale | Keutzer Timothy | Chief Operating Officer | 18,652 0.0323% | $2.36 | $44,019 | -9.30% | |
| 2026-02-04 | Sale | Keutzer Timothy | Chief Operating Officer | 3,471 0.006% | $2.24 | $7,775 | -3.71% | |
| 2026-02-03 | Sale | Keutzer Timothy | Chief Operating Officer | 24,224 0.043% | $2.14 | $51,839 | +3.27% | |
| 2026-02-02 | Sale | Rajavelu Esther | See Remarks | 18,442 0.0324% | $2.20 | $40,572 | -1.12% | |
| 2026-02-02 | Sale | Keutzer Timothy | Chief Operating Officer | 18,891 0.0332% | $2.20 | $41,560 | -1.12% | |
| 2025-11-07 | Sale | Rajavelu Esther | See Remarks | 40,270 0.0698% | $2.37 | $95,440 | -6.50% | |
| 2025-08-28 | Sale | Keutzer Timothy | Chief Operating Officer | 1,695 0.003% | $1.97 | $3,339 | +16.50% | |
| 2025-08-28 | Sale | Mahadevia Ankit | director | 6,572 0.0115% | $1.97 | $12,947 | +16.50% | |
| 2025-02-05 | Sale | Shukla Sath | CEO & President | 155,333 0.2951% | $0.78 | $121,160 | +150.86% | |
| 2025-02-05 | Sale | Keutzer Timothy | Chief Operating Officer | 56,537 0.1074% | $0.78 | $44,099 | +150.86% | |
| 2025-02-05 | Sale | Rajavelu Esther | CFO & CBO | 20,689 0.0393% | $0.78 | $16,137 | +150.86% | |
| 2025-02-05 | Sale | Mahadevia Ankit | director | 69,219 0.1315% | $0.78 | $53,991 | +150.86% | |
| 2024-11-08 | Sale | Rajavelu Esther | CFO & CBO | 17,245 0.0314% | $1.30 | $22,419 | -12.12% | |
| 2024-11-07 | Sale | Rajavelu Esther | CFO & CBO | 23,351 0.0429% | $1.31 | $30,590 | -11.07% | |
| 2024-08-27 | Sale | Shukla Sath | CEO & President | 2,757 0.005% | $1.35 | $3,722 | -15.58% | |
| 2024-08-27 | Sale | Mahadevia Ankit | director | 5,912 0.0107% | $1.35 | $7,981 | -15.58% | |
| 2024-08-27 | Sale | Keutzer Timothy | Chief Operating Officer | 2,213 0.004% | $1.35 | $2,988 | -15.58% | |
| 2024-08-05 | Sale | Shukla Sath | CEO and President | 17,641 0.0319% | $1.31 | $23,110 | -13.06% |
| Aquilo Capital, L.P. | 5321231 9.1375% | $5.53M | 3 | 0 | ||
| Aquilo Capital Management, LLC | 10 percent owner | 5207796 8.9428% | $5.42M | 21 | 11 | |
| FORMELA JEAN FRANCOIS | director | 2408128 4.1352% | $2.5M | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1934006 3.321% | $2.01M | 2 | 0 | <0.0001% |
| Goyal Vikas | director | 1854006 3.1837% | $1.93M | 1 | 0 | <0.0001% |
| Breum Casper | director | 1091774 1.8748% | $1.14M | 1 | 0 | <0.0001% |
| Sendek Joel | Chief Financial Officer | 15181 0.0261% | $15,788.24 | 1 | 1 | <0.0001% |
| Larkin Cristina | Chief Operating Officer | 1500 0.0026% | $1,560.00 | 1 | 2 | <0.0001% |
$5,831,763 | 118 | -33.78% | $66.68M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$103,288,323 | 51 | 4.78% | $56.52M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$909,129 | 37 | 42.19% | $67.23M |
| Increased Positions | 30 | +62.5% | 11M | +141.96% |
| Decreased Positions | 18 | -37.5% | 2M | -19.42% |
| New Positions | 15 | New | 11M | New |
| Sold Out Positions | 6 | Sold Out | 238,264 | Sold Out |
| Total Postitions | 60 | +25% | 18M | +122.55% |
| Vanguard Group Inc | $4,676.00 | 3.55% | 1.99M | +39,474 | +2.02% | 2025-09-30 |
| Anson Funds Management Lp | $3,768.00 | 2.86% | 1.6M | -11,900 | -0.74% | 2025-09-30 |
| Renaissance Technologies Llc | $3,414.00 | 2.59% | 1.45M | +620,600 | +74.58% | 2025-09-30 |
| Geode Capital Management, Llc | $1,240.00 | 0.94% | 527,477 | +16,778 | +3.29% | 2025-09-30 |
| Blackrock, Inc. | $1,022.00 | 0.78% | 434,768 | 0 | 0% | 2025-09-30 |
| Informed Momentum Co Llc | $664.00 | 0.5% | 282,445 | +43,305 | +18.11% | 2025-09-30 |
| Ionic Capital Management Llc | $491.00 | 0.37% | 208,725 | +58,725 | +39.15% | 2025-09-30 |
| State Street Corp | $449.00 | 0.34% | 190,951 | +37,500 | +24.44% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $354.00 | 0.27% | 150,516 | +150,516 | New | 2025-09-30 |
| Northern Trust Corp | $305.00 | 0.23% | 129,643 | +28,812 | +28.57% | 2025-09-30 |